Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer
Anthony Elias(University of Colorado Cancer Center), Jennifer K. Richer(University of Colorado Anschutz Medical Campus), Peter Kabos(University of Colorado Anschutz Medical Campus), Tessa McSpadden(University of Colorado Cancer Center), Elena Shagisultanova(University of Colorado Anschutz Medical Campus), Julia Wulfkuhle(University of California, San Francisco), Kimberly R. Jordan(University of Colorado Anschutz Medical Campus), Jill E. Slansky(University of Colorado Anschutz Medical Campus), Andrew Goodspeed(University of Colorado Cancer Center), Dexiang Gao(University of Colorado Cancer Center), Jennifer R. Diamond(University of Colorado Anschutz Medical Campus), Alyse Staley(University of Colorado Anschutz Medical Campus), Rosa I. Gallagher(George Mason University), Sharon B. Sams(University of Colorado Denver), Nicole S. Spoelstra(University of Colorado Anschutz Medical Campus), Vida Alami(University of Colorado Cancer Center), Gregory A. Vidal(West Cancer Center), Kathryn L. Zolman(University of Colorado Anschutz Medical Campus), Virginia F. Borges(University of Colorado Anschutz Medical Campus), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Monica Fornier(Cornell University)
Cited by 9
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells
|Journal of Biological Chemistry|2002|574